RIGL Rigel Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 4, 2026
$47.15
· of 52w range
· above low
· to high
$24.9552w low
$52.2452w high
Market Cap
$863M
P/E (TTM)
2.8
EPS (TTM)
$16.89
Revenue (TTM)
$277M
your badges
52W Range
$25–$52
Analyst Rating
STRONG BUY
Price Target
$63
P/E
2.8
ROE
126.9%
Net Profit Margin
116.3%
Your badge strip is empty — pin a metric anywhere on this page.
RIGL Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$47.15
Market Cap
$863M
P/E (TTM)
2.8
EPS (TTM)
$16.89
Revenue (TTM)
$277M
ROE (TTM)
126.9%
52W Range
$25–$52
RIGL Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| June 27, 2024 | 1-for-10 | Reverse |
| June 25, 2003 | 1-for-9 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$294M2016-12-31 → 2025-12-31
EPS$19.482019-12-31 → 2025-12-31
Free Cash Flow·2016-12-31 → 2022-12-31
Net margin116.3%2018-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | RIGL | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | 2.85Y avg ≈-47.2 | ≈-47.2 | · | · | |
| P/S | 2.95Y avg ≈15.6 | ≈15.6 | 12.6 | Undervalued | |
| P/B | 2.25Y avg ≈-7.4 | ≈-7.4 | 4.6 | Undervalued | |
| Price / Cash Flow | 11.45Y avg ≈63.4 | ≈63.4 | · | · | |
| Price / Tangible Book | 2.4 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | RIGL | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | 31.5%5Y avg ≈-3.2% | ≈-3.2% | -180.0% | Top tier | |
| EBITDA Margin (TTM) | 32.4%5Y avg ≈-2.2% | ≈-2.2% | -180.0% | Top tier | |
| Pretax Margin (TTM) | 30.9%5Y avg ≈-6.0% | ≈-6.0% | -170.5% | Top tier | |
| Net Profit Margin (TTM) | 116.3%5Y avg ≈10.5% | ≈10.5% | -170.6% | Top tier | |
| ROA (TTM) | 88.5%5Y avg ≈9.8% | ≈9.8% | -39.1% | Top tier | |
| ROE (TTM) | 126.9%5Y avg ≈47.1% | ≈47.1% | -50.7% | Top tier | |
| ROIC | 96.5%5Y avg ≈251.5% | ≈251.5% | -59.1% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | RIGL | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 1.95Y avg ≈2.1 | ≈2.1 | 11.7 | Low liquidity | |
| Quick Ratio (MRQ) | 1.65Y avg ≈1.9 | ≈1.9 | 4.9 | Below avg |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | RIGL | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 64.1%5Y avg ≈26.5% | ≈26.5% | · | · | |
| Revenue CAGR 3Y | 34.8%5Y avg ≈14.5% | ≈14.5% | · | · | |
| Revenue CAGR 5Y | 22.1% | · | · | · | |
| EPS YoY | 1867.7% | · | · | · | |
| Net Income YoY | 1999.1% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | RIGL | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.95Y avg ≈1.0 | ≈1.0 | 0.5 | Top tier | |
| Inventory Turnover | 2.25Y avg ≈1.4 | ≈1.4 | · | · | |
| Receivables Turnover | 6.35Y avg ≈5.7 | ≈5.7 | · | · | |
| Revenue / Employee | ≈$1.7M | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
111.8%
Next Report
Nov 02, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 3, 2026 | $0.88 | $0.63 | 39.2% |
| March 31, 2026 | $0.44 | $0.78 | -43.2% | |
| Dec. 31, 2025 | $1.15 | $1.27 | -9.6% | |
| Sept. 30, 2025 | $1.46 | $0.87 | 67.5% | |
| June 30, 2025 | $3.28 | $2.63 | 24.6% | |
| March 31, 2025 | $0.63 | $0.09 | 592.3% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $294M | $179M | $117M | $120M | $149M | $109M | $59M | $45M | $4M | $20M | |
| Cost of Revenue | $20M | $19M | $7M | $2M | $1M | $895.0K | $906.0K | $287.0K | · | · | |
| R&D Expense | $33M | $23M | $25M | · | · | · | · | · | · | · | |
| SG&A Expense | $116M | $113M | $106M | $112M | $92M | $77M | $75M | $70M | $38M | $21M | |
| Operating Expenses | $169M | $155M | $137M | $176M | $162M | $138M | $128M | $117M | $84M | $90M | |
| Operating Income | $125M | $24M | $-20M | $-56M | $-12M | $-29M | $-69M | $-73M | $-80M | $-70M | |
| Interest Expense | · | $8M | $7M | $4M | $5M | $1M | $335.0K | · | · | · | |
| Interest Income | $4M | $2M | $2M | $684.0K | $47.0K | $582.0K | $3M | $2M | $892.0K | $437.0K | |
| Pretax Income | $122M | $18M | $-25M | $-59M | $-17M | $-30M | $-67M | · | · | · | |
| Income Tax | $-245M | $881.0K | $0 | · | $605.0K | · | · | $0 | $0 | $0 | |
| Net Income | $367M | $17M | $-25M | $-59M | $-18M | $-30M | $-67M | $-70M | $-78M | $-69M | |
| EPS (Basic) | $20.40 | $0.99 | $-1.44 | $-3.44 | $-0.11 | $-0.18 | $-0.40 | · | · | · | |
| EPS (Diluted) | $19.48 | $0.99 | $-1.44 | $-3.44 | $-0.11 | $-0.18 | $-0.40 | · | · | · | |
| Shares (Basic) | 17,987,000 | 17,579,000 | 17,401,000 | 17,049,000 | 170,492,000 | 168,754,000 | 167,400,000 | · | · | · | |
| Shares (Diluted) | 18,840,000 | 17,687,000 | 17,401,000 | 17,049,000 | 170,492,000 | 168,754,000 | 167,400,000 | · | · | · | |
| EBITDA | $128M | $26M | $-19M | $-55M | $-11M | $-28M | $-68M | $-72M | · | $-69M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41M | $57M | $33M | $24M | $19M | $30M | $23M | $76M | $38M | $18M | |
| Short-term Investments | $114M | $21M | $24M | $34M | $106M | $27M | $76M | $52M | $77M | $57M | |
| Receivables | $52M | $42M | $31M | $40M | $15M | $16M | $10M | $4M | $0 | $0 | |
| Inventory | $12M | $6M | $6M | $9M | $7M | $2M | $1M | $894.0K | · | · | |
| Prepaid Expense | $22M | $10M | $6M | $8M | $7M | $14M | $9M | $3M | $2M | $1M | |
| Other Current Assets | $5M | $5M | · | · | · | · | · | · | · | · | |
| Current Assets | $240M | $135M | $99M | $116M | $154M | $89M | $119M | $137M | $117M | $76M | |
| PP&E (Net) | $30.0K | $92.0K | $165.0K | $857.0K | $2M | $3M | $2M | $1M | $875.0K | $1M | |
| PP&E (Gross) | $347.0K | $353.0K | $2M | $12M | $17M | $16M | $15M | $14M | $13M | $20M | |
| Accum. Depreciation | $317.0K | $261.0K | $2M | $11M | $15M | $14M | $13M | $13M | $12M | $19M | |
| Intangibles | $25M | $27M | $14M | $15M | · | · | · | · | · | · | |
| Other Non-current Assets | $2M | $2M | $3M | $640.0K | $974.0K | $824.0K | $696.0K | $735.0K | $803.0K | $764.0K | |
| Total Assets | $514M | $164M | $117M | $134M | $167M | $110M | $148M | $139M | $119M | $78M | |
| Accounts Payable | $7M | $3M | $7M | $23M | $4M | $4M | $4M | $6M | $3M | $6M | |
| Accrued Liabilities | · | · | · | · | $4M | $4M | $3M | · | · | · | |
| Current Liabilities | $99M | $63M | $53M | $65M | $64M | $41M | $58M | $28M | $18M | $23M | |
| Capital Leases | $395.0K | $0 | $285.0K | $972.0K | $759.0K | $11M | $19M | · | · | · | |
| Other Non-current Liabilities | $0 | $40M | $40M | $42M | $53M | $5M | $5M | · | $38.0K | $2.0K | |
| Total Liabilities | $122M | $161M | $146M | $148M | $137M | · | · | · | · | · | |
| Long-term Debt | $52M | $60M | $60M | $40M | $20M | $20M | $10M | · | · | · | |
| Common Stock | $18.0K | $18.0K | $17.0K | $174.0K | $172.0K | $169.0K | $168.0K | $167.0K | $147.0K | $100.0K | |
| Retained Earnings | $-1.02B | $-1.39B | $-1.41B | $-1.38B | $-1.32B | $-1.31B | $-1.28B | $-1.21B | $-1.14B | $-1.06B | |
| AOCI | $181.0K | $10.0K | $8.0K | $-153.0K | $-102.0K | $-4.0K | $23.0K | $-24.0K | $-82.0K | $-18.0K | |
| Stockholders' Equity | $391M | $3M | $-29M | $-14M | $30M | $34M | $54M | $110M | $101M | $55M | |
| Liabilities + Equity | $514M | $164M | $117M | $134M | $167M | $110M | $148M | $139M | $119M | $78M | |
| Shares Outstanding | 18,310,934 | 17,710,216 | 17,482,513 | 173,398,645 | 171,602,226 | 169,316,782 | 167,987,850 | 167,171,505 | 146,814,906 | 99,269,418 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $1M | $998.0K | $1M | $706.0K | $683.0K | $594.0K | $465.0K | $941.0K | |
| Stock-based Comp | $13M | $12M | $9M | $12M | $9M | $7M | $9M | $8M | $6M | $7M | |
| Deferred Tax | $-246M | $0 | $0 | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $2M | $2M | $1M | $100.0K | · | · | · | · | · | · | |
| Restructuring | · | · | · | $1M | $4M | · | · | · | · | $6M | |
| Other Non-cash | $-61M | $-635.0K | $9M | $-29M | $13M | $-30M | $16M | $3M | · | · | |
| Operating Cash Flow | $76M | $31M | $-6M | $-74M | $6M | $-52M | $-42M | $-59M | $-78M | $-76M | |
| CapEx | · | · | · | $450.0K | $627.0K | $1M | $1M | $1M | $164.0K | $804.0K | |
| Investing Cash Flow | $-92M | $4M | $-4M | $73M | $-80M | $47M | $-24M | $25M | $-19M | $25M | |
| Stock Issued | · | · | · | · | · | · | · | $67M | $114M | $24M | |
| Net Stock Activity | · | · | · | · | · | · | · | $67M | · | $30M | |
| Financing Cash Flow | $601.0K | $-12M | $18M | $7M | $63M | $13M | $11M | $72M | $118M | $25M | |
| Net Change in Cash | · | · | · | · | · | · | · | $38M | $21M | $-26M | |
| Taxes Paid | $1M | $331.0K | $81.0K | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | $-74M | $5M | $-53M | $-43M | $-60M | · | $-77M | |
| Levered FCF | · | · | · | · | $221.1K | · | · | · | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 42.6% | 13.5% | -17.5% | -46.2% | -8.4% | -26.7% | -116.5% | -163.3% | · | · | |
| Net Margin | 124.7% | 9.8% | -21.5% | -48.7% | -12.0% | -27.4% | -112.8% | -158.3% | · | · | |
| Pretax Margin | 41.4% | 10.2% | -21.5% | -48.7% | -11.6% | · | · | · | · | · | |
| EBITDA Margin | 43.5% | 14.7% | -16.5% | -45.4% | -7.6% | -26.0% | -115.4% | -162.0% | · | · | |
| ROA | 108.3% | 12.4% | -20.0% | -38.8% | -12.9% | -23.1% | -46.7% | -54.6% | · | · | |
| ROE | 155.1% | -308.2% | 83.0% | 350.2% | -44.8% | -70.0% | -109.0% | -66.1% | · | · | |
| ROIC | 96.5% | 700.5% | · | · | -42.6% | · | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.4 | 2.1 | 1.9 | 1.8 | 2.4 | 2.2 | 2.0 | 4.9 | · | 3.4 | |
| Quick Ratio | 2.1 | 1.9 | 1.6 | 1.5 | 2.2 | 1.8 | 1.9 | 4.8 | · | 3.3 | |
| Interest Coverage | · | 3.1 | -3.0 | -15.0 | -2.6 | -21.4 | -206.2 | · | · | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.9 | 1.3 | 0.9 | 0.8 | 1.1 | 0.8 | 0.4 | 0.3 | · | · | |
| Inventory Turnover | 2.2 | 3.2 | 1.0 | 0.2 | 0.3 | 0.6 | 0.8 | 0.6 | · | · | |
| Receivables Turnover | 6.3 | 5.0 | 3.3 | 4.3 | 9.5 | 8.3 | 8.4 | 21.8 | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $21.38 | $0.19 | $-0.16 | $-0.08 | $0.18 | $0.20 | $0.32 | $0.66 | · | $0.55 | |
| Revenue / Share | $15.62 | $10.14 | $0.67 | $0.70 | $0.88 | · | · | · | · | · | |
| Cash Flow / Share | $4.02 | $1.78 | $-0.03 | $-0.43 | $0.03 | · | · | · | · | · | |
| Cash / Share | $2.22 | $3.20 | $0.19 | $0.14 | $0.11 | $0.18 | $0.13 | $0.46 | · | $0.18 | |
| EPS (TTM) | $19.48 | $0.99 | $-1.44 | $-3.44 | $-0.11 | $-0.18 | $-0.40 | · | · | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 64.1% | 53.4% | -2.8% | -19.4% | 37.4% | · | · | · | · | · | |
| Revenue CAGR 3Y | 34.8% | 6.3% | 2.5% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 22.1% | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 1867.7% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 1999.1% | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $294M | $179M | $117M | $120M | $149M | $109M | $59M | $45M | $4M | $20M | |
| Net Income TTM | $367M | $17M | $-25M | $-59M | $-18M | $-30M | $-67M | $-70M | $-78M | $-69M | |
| Market Cap | $784M | $298M | $2.53B | $2.60B | $4.55B | $5.93B | $3.59B | $3.84B | · | $2.36B | |
| P/E | 2.2 | 17.0 | -10.1 | -4.4 | -240.9 | -194.4 | -53.5 | · | · | · | |
| P/S | 2.7 | 1.7 | 21.7 | 21.6 | 30.5 | 54.6 | 60.6 | 86.4 | · | 115.9 | |
| P/B | 2.0 | 90.6 | -88.5 | -191.0 | 149.7 | 174.2 | 66.8 | 35.0 | · | 42.9 | |
| P / Tangible Book | 2.1 | · | · | · | 149.7 | 174.2 | · | · | · | · | |
| P / Cash Flow | 10.4 | 9.5 | -441.4 | -35.3 | 773.6 | -113.6 | -86.6 | -65.4 | · | -31.1 | |
| P / FCF | · | · | · | -35.0 | 866.0 | -110.9 | -83.7 | -64.2 | · | -30.8 | |
| Earnings Yield | 45.5% | 5.9% | -9.9% | -22.9% | -0.42% | -0.51% | -1.9% | · | · | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $79M | $59M | $70M | $69M | $102M | $53M | $58M | $55M | $37M | $30M | $28M | $27M | $26M | $22M | $30M | $17M | |
| Cost of Revenue | $9M | $5M | $6M | $5M | $5M | $4M | $6M | $8M | $3M | $2M | $1M | $1M | $977.0K | $250.0K | $1M | $121.0K | |
| R&D Expense | $14M | $12M | · | · | $7M | $8M | · | · | · | · | · | · | · | · | · | · | |
| SG&A Expense | $33M | $31M | $30M | $29M | $29M | $28M | $30M | $27M | $28M | $28M | $25M | $26M | $28M | $26M | $27M | $27M | |
| Operating Expenses | $55M | $47M | $47M | $41M | $41M | $41M | $41M | $41M | $36M | $36M | $33M | $32M | $39M | $41M | $43M | $43M | |
| Operating Income | $24M | $12M | $23M | $28M | $61M | $13M | $17M | $14M | $447.0K | $-7M | $-4M | $-5M | $-13M | $-18M | $-13M | $-26M | |
| Interest Expense | · | · | · | $2M | $2M | $2M | · | $2M | $2M | $2M | $2M | $2M | $1M | $826.0K | $569.0K | $1M | |
| Interest Income | $789.0K | $1M | $1M | $1M | $753.0K | $591.0K | $522.0K | $425.0K | $552.0K | $593.0K | $672.0K | $529.0K | $393.0K | $192.0K | $42.0K | $21.0K | |
| Pretax Income | $24M | $12M | $23M | $28M | $60M | $12M | $15M | $12M | $-1M | $-8M | · | · | · | $-19M | $-13M | $-27M | |
| Income Tax | $6M | $3M | $-245M | $-280.0K | $369.0K | $65.0K | $881.0K | $0 | $0 | $0 | · | · | · | $0 | $0 | $0 | |
| Net Income | $17M | $9M | $268M | $28M | $60M | $11M | $14M | $12M | $-1M | $-8M | $-6M | $-7M | $-14M | $-19M | $-13M | $-27M | |
| EPS (Basic) | $0.93 | $0.47 | $14.88 | $1.55 | $3.33 | $0.64 | $0.81 | $0.71 | $-0.06 | $-0.47 | $-0.33 | $-0.38 | $-0.08 | $-0.11 | $-0.08 | $-0.16 | |
| EPS (Diluted) | $0.88 | $0.44 | $14.11 | $1.46 | $3.28 | $0.63 | $0.82 | $0.70 | $-0.06 | $-0.47 | $-0.33 | $-0.38 | $-0.08 | $-0.11 | $-0.08 | $-0.16 | |
| Shares (Basic) | 18,541,000 | 18,412,000 | · | 18,038,000 | 17,885,000 | 17,808,000 | · | 17,600,000 | 17,549,000 | 17,520,000 | 17,436,000 | 17,356,000 | 173,568,000 | 172,836,000 | 172,147,000 | 171,774,000 | |
| Shares (Diluted) | 19,570,000 | 19,686,000 | · | 19,156,000 | 18,162,000 | 18,169,000 | · | 17,648,000 | 17,549,000 | 17,520,000 | 17,436,000 | 17,356,000 | 173,568,000 | 172,836,000 | 172,147,000 | 171,774,000 | |
| EBITDA | $24M | $12M | · | $28M | $61M | $13M | · | $14M | $447.0K | $-7M | $-4M | $-5M | $-12M | $-18M | $-13M | $-26M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $61M | $24M | $41M | $49M | $53M | $46M | $57M | $52M | $36M | $26M | $45M | $49M | $40M | $30M | $27M | $25M | |
| Short-term Investments | $35M | $122M | $114M | $89M | $55M | $31M | $21M | $9M | $13M | $24M | $17M | $16M | $18M | $52M | $62M | $83M | |
| Receivables | $56M | $50M | $52M | $46M | $40M | $42M | $42M | $31M | $29M | $28M | $24M | $21M | $29M | $16M | $17M | $15M | |
| Inventory | $14M | $12M | $12M | $13M | $10M | $5M | $6M | $5M | $8M | $7M | $6M | $11M | $11M | $7M | $6M | $7M | |
| Prepaid Expense | $20M | $26M | $22M | $19M | $17M | $23M | $10M | $10M | $9M | $9M | $3M | $5M | $8M | $6M | $8M | $9M | |
| Other Current Assets | $5M | $7M | $5M | $6M | $5M | $6M | $5M | · | · | · | · | · | · | · | · | · | |
| Current Assets | $186M | $234M | $240M | $215M | $175M | $147M | $135M | $106M | $95M | $92M | $95M | $101M | $107M | $110M | $121M | $139M | |
| PP&E (Net) | · | · | $30.0K | $54.0K | $57.0K | $76.0K | $92.0K | $99.0K | $115.0K | $140.0K | $190.0K | $215.0K | $294.0K | $2M | $2M | $2M | |
| PP&E (Gross) | · | · | $347.0K | · | · | · | $353.0K | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $317.0K | · | · | · | $261.0K | · | · | · | · | · | · | · | · | · | |
| Intangibles | $94M | $24M | $25M | $25M | $26M | $27M | $27M | $28M | $28M | $29M | · | · | · | · | · | · | |
| Other Non-current Assets | $3M | $2M | $2M | $1M | $4M | $2M | $2M | $5M | $5M | $4M | $5M | $541.0K | $542.0K | $484.0K | $403.0K | $464.0K | |
| Total Assets | $521M | $505M | $514M | $243M | $207M | $176M | $164M | $139M | $128M | $127M | $115M | $117M | $124M | $116M | $128M | $149M | |
| Accounts Payable | $4M | $4M | $7M | $4M | $7M | $4M | $3M | $4M | $6M | $9M | $8M | $5M | $6M | $3M | $2M | $5M | |
| Current Liabilities | $96M | $89M | $99M | $94M | $87M | $67M | $63M | $54M | $59M | $73M | $48M | $44M | $46M | $47M | $55M | $59M | |
| Capital Leases | $58.0K | $228.0K | $395.0K | $556.0K | $714.0K | $864.0K | $0 | · | · | $100.0K | $466.0K | $628.0K | $802.0K | · | · | · | |
| Other Non-current Liabilities | · | · | $0 | · | · | $40M | $40M | $40M | $40M | $40M | $39M | $41M | $42M | $49M | $47M | $53M | |
| Total Liabilities | $96M | $105M | $122M | $125M | $125M | $157M | $161M | $154M | $158M | $158M | $147M | $145M | $148M | · | · | · | |
| Long-term Debt | · | $45M | $52M | $60M | $60M | $60M | · | $60M | $60M | $60M | $60M | $60M | $60M | $40M | $30M | $30M | |
| Common Stock | $18.0K | $18.0K | $18.0K | $18.0K | $18.0K | $18.0K | $18.0K | $17.0K | $17.0K | $175.0K | $175.0K | $175.0K | $174.0K | $173.0K | $173.0K | $172.0K | |
| Retained Earnings | $-997M | $-1.01B | $-1.02B | $-1.29B | $-1.32B | $-1.38B | $-1.39B | $-1.40B | $-1.42B | $-1.42B | $-1.41B | $-1.40B | $-1.40B | $-1.38B | $-1.36B | $-1.35B | |
| AOCI | $-148.0K | $-128.0K | $181.0K | $96.0K | $6.0K | $-2.0K | $10.0K | $11.0K | $-9.0K | $-5.0K | $-15.0K | $-25.0K | $-27.0K | $-286.0K | $-438.0K | $-416.0K | |
| Stockholders' Equity | $425M | $400M | $391M | $118M | $82M | $19M | $3M | $-15M | $-30M | $-32M | $-32M | $-28M | $-24M | $-20M | $-4M | $7M | |
| Liabilities + Equity | $521M | $505M | $514M | $243M | $207M | $176M | $164M | $139M | $128M | $127M | $115M | $117M | $124M | $116M | $128M | $149M | |
| Shares Outstanding | · | · | 18,310,934 | · | · | · | 17,710,216 | · | · | · | · | · | · | · | · | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $848.0K | $597.0K | $601.0K | $603.0K | $607.0K | $604.0K | $604.0K | $611.0K | $613.0K | $400.0K | $292.0K | $296.0K | $357.0K | $240.0K | $237.0K | $237.0K | |
| Stock-based Comp | $7M | $3M | $3M | $3M | $3M | $3M | $2M | $3M | $3M | $5M | $2M | $2M | $3M | $3M | $2M | $3M | |
| Amort. of Intangibles | · | $600.0K | $600.0K | $600.0K | $600.0K | $600.0K | $500.0K | $600.0K | $600.0K | $400.0K | $300.0K | $300.0K | $300.0K | · | · | · | |
| Other Non-cash | · | $-10M | · | · | · | $-16M | · | · | · | $-2M | · | · | $6M | · | · | $-2M | |
| Operating Cash Flow | $31M | $3M | $22M | $24M | $31M | $-893.0K | $15M | $22M | $302.0K | $-5M | $-1M | $6M | $-4M | $-13M | $-13M | $-26M | |
| CapEx | · | · | · | · | · | · | · | · | · | · | · | · | · | $189.0K | $-36.0K | $224.0K | |
| Investing Cash Flow | $17M | $-8M | $-25M | $-33M | $-23M | $-11M | $-11M | $4M | $11M | $313.0K | $-1M | $3M | $777.0K | $10M | $21M | $23M | |
| Stock Repurchased | $511.0K | $4M | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | · | $-4M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-12M | $-11M | $-5M | $4M | $418.0K | $484.0K | $1M | $-10M | $-752.0K | $-3M | $-869.0K | $-373.0K | $19M | $6M | $-6M | $9M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $-26M | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $-27M |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 29.9% | 20.2% | · | 40.9% | 60.1% | 23.9% | · | 25.4% | 1.2% | -23.6% | -15.9% | -19.6% | -48.8% | -82.1% | -43.5% | -156.9% | |
| Net Margin | 22.0% | 14.7% | · | 40.2% | 58.6% | 21.5% | · | 22.5% | -2.8% | -27.9% | -20.2% | -24.6% | -51.9% | -85.0% | -45.2% | -164.0% | |
| Pretax Margin | 30.0% | 19.8% | · | 39.8% | 59.0% | 21.6% | · | · | · | · | · | · | · | -85.0% | -45.2% | -164.0% | |
| EBITDA Margin | 29.9% | 21.2% | · | 40.9% | 60.1% | 25.1% | · | 25.4% | 1.2% | -22.2% | -15.9% | -19.6% | -47.4% | -82.1% | -43.5% | -155.5% | |
| ROA | 4.8% | 2.5% | · | 14.6% | 35.6% | 7.6% | · | 9.8% | -0.84% | -6.6% | -4.9% | -5.4% | -9.9% | -12.6% | -8.2% | -15.0% | |
| ROE | 6.8% | 4.1% | · | 54.2% | 229.2% | -174.7% | · | -53.5% | 3.5% | 29.5% | 22.0% | 41.5% | 155.1% | -127.6% | -41.9% | -64.5% | |
| ROIC | 4.1% | 2.2% | · | 24.4% | 74.1% | 68.4% | · | · | · | · | · | · | · | 92.8% | 352.6% | -386.3% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 2.6 | · | 2.3 | 2.0 | 2.2 | · | 2.0 | 1.6 | 1.3 | 2.0 | 2.3 | 2.4 | 2.3 | 2.2 | 2.3 | |
| Quick Ratio | 1.6 | 2.2 | · | 1.9 | 1.7 | 1.8 | · | 1.7 | 1.3 | 1.1 | 1.8 | 1.9 | 1.9 | 2.1 | 1.9 | 2.1 | |
| Interest Coverage | · | · | · | 15.0 | 32.6 | 6.9 | · | 6.8 | 0.2 | -3.7 | -2.4 | -2.8 | -10.6 | -22.3 | -22.8 | -21.8 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.4 | 0.6 | 0.4 | · | 0.4 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 | 0.1 | |
| Inventory Turnover | 0.7 | 0.6 | · | 0.5 | 0.5 | 0.8 | · | 1.5 | 0.3 | 0.2 | 0.2 | 0.1 | 0.1 | 0.0 | 0.2 | 0.0 | |
| Receivables Turnover | 1.6 | 1.3 | · | 1.8 | 3.0 | 1.5 | · | 2.0 | 1.5 | 1.0 | 1.4 | 1.4 | 1.2 | 1.5 | 1.7 | 0.2 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $4.02 | $2.99 | · | $3.63 | $5.60 | $2.94 | · | $3.13 | $2.10 | $0.17 | $0.16 | $0.15 | $0.15 | $0.13 | $0.17 | $0.10 | |
| Cash Flow / Share | · | $0.14 | · | · | · | $-0.05 | · | · | · | $-0.03 | · | · | $-0.02 | · | · | $-0.15 | |
| EPS (TTM) | $16.89 | $19.29 | · | $6.19 | $5.43 | $2.09 | · | $-0.48 | $-1.51 | $-1.83 | $-3.88 | $-3.66 | $-3.36 | $-0.48 | $-0.49 | $-0.49 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $277M | $300M | · | $282M | $268M | $203M | · | $157M | $130M | $120M | $132M | $127M | $130M | $89M | $89M | $85M | |
| Net Income TTM | $322M | $364M | · | $113M | $98M | $37M | · | $4M | $-14M | $-20M | $-24M | $-38M | $-45M | $-83M | $-85M | $-85M | |
| P/E | 2.3 | 1.4 | · | 4.6 | 3.4 | 8.6 | · | -33.7 | -5.4 | -8.1 | -2.8 | -3.5 | -3.9 | -24.6 | -23.1 | -61.0 | |
| Earnings Yield | 43.2% | 71.3% | · | 21.9% | 29.0% | 11.6% | · | -3.0% | -18.4% | -12.4% | -35.9% | -28.4% | -25.4% | -4.1% | -4.3% | -1.6% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $294M | $179M | $117M | $120M | $149M |
| Operating Margin % | 42.6% | 13.5% | -17.5% | -46.2% | -8.4% |
| Net Income | $367M | $17M | $-25M | $-59M | $-18M |
| Diluted EPS | $19.48 | $0.99 | $-1.44 | $-3.44 | $-0.11 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 2.4 | 2.1 | 1.9 | 1.8 | 2.4 |
| Quick Ratio | 2.1 | 1.9 | 1.6 | 1.5 | 2.2 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | · | · | · | $-74M | $5M |
Institutional owners (13F) 168 filers · $637.8M total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
168
Value held
$637.8M
New positions
31
Exited positions
23
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 31 (+13 vs prior Q) | 23 (-21 vs prior Q) | 53 (-15 vs prior Q) | 57 (+9 vs prior Q) | +269K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $75,885,690 | 1,939,818 | 11.90% | Shares |
| Soleus Capital Management, L.P. | $72,117,876 | 1,843,504 | 11.31% | Shares |
| ARMISTICE CAPITAL, LLC | $65,408,640 | 1,672,000 | 10.26% | Shares |
| VANGUARD GROUP INC | $44,475,015 | 1,038,408 | 6.97% | Shares |
| STATE STREET CORP | $40,684,565 | 1,039,994 | 6.38% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $30,713,386 | 785,107 | 4.82% | Shares |
| AMERICAN CENTURY COMPANIES INC | $29,016,008 | 741,718 | 4.55% | Shares |
| D. E. Shaw & Co., Inc. | $21,224,126 | 542,539 | 3.33% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $18,906,353 | 483,175 | 2.96% | Shares |
| MARSHALL WACE, LLP | $14,372,414 | 367,393 | 2.25% | Shares |
| CM Management, LLC | $9,780,000 | 250,000 | 1.53% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $9,143,439 | 233,728 | 1.43% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $8,917,295 | 227,951 | 1.40% | Shares |
| GOLDMAN SACHS GROUP INC | $8,871,634 | 226,780 | 1.39% | Shares |
| TWO SIGMA INVESTMENTS, LP | $8,120,451 | 207,578 | 1.27% | Shares |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $7,628,000 | 195,000 | 1.20% | Shares |
| MORGAN STANLEY | $7,278,237 | 186,049 | 1.14% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $6,049,008 | 154,627 | 0.95% | Shares |
| NORTHERN TRUST CORP | $5,726,425 | 146,381 | 0.90% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $5,705,496 | 145,846 | 0.89% | Shares |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $5,131,644 | 131,177 | 0.80% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $4,882,214 | 124,801 | 0.77% | Shares |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $4,858,078 | 124,184 | 0.76% | Shares |
| Nuveen, LLC | $4,849,354 | 123,961 | 0.76% | Shares |
| BANK OF AMERICA CORP /DE/ | $4,831,556 | 123,506 | 0.76% | Shares |
| FRANKLIN RESOURCES INC | $4,825,999 | 123,364 | 0.76% | Shares |
| UBS Group AG | $4,809,960 | 122,954 | 0.75% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $4,762,195 | 121,733 | 0.75% | Shares |
| GLOBEFLEX CAPITAL L P | $4,407,729 | 112,672 | 0.69% | Shares |
| CenterBook Partners LP | $4,286,574 | 109,575 | 0.67% | Shares |
| Bank of New York Mellon Corp | $4,233,132 | 108,209 | 0.66% | Shares |
| FMR LLC | $3,759,903 | 96,112 | 0.59% | Shares |
| RITHOLTZ WEALTH MANAGEMENT | $3,694,884 | 94,450 | 0.58% | Shares |
| JANUS HENDERSON GROUP PLC | $3,674,114 | 135,877 | 0.58% | Shares |
| MILLENNIUM MANAGEMENT LLC | $3,665,114 | 93,689 | 0.57% | Shares |
| FIRST TRUST ADVISORS LP | $3,182,099 | 81,342 | 0.50% | Shares |
| Empowered Funds, LLC | $3,097,678 | 79,184 | 0.49% | Shares |
| Brandywine Global Investment Management, LLC | $3,065,343 | 71,570 | 0.48% | Shares |
| Russell Investments Group, Ltd. | $2,973,196 | 76,002 | 0.47% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $2,687,544 | 68,700 | 0.42% | Call option |
| Squarepoint Ops LLC | $2,607,661 | 66,658 | 0.41% | Shares |
| BURNEY CO/ | $2,181,683 | 55,769 | 0.34% | Shares |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $2,159,424 | 55,200 | 0.34% | Shares |
| WELLS FARGO & COMPANY/MN | $2,131,727 | 54,492 | 0.33% | Shares |
| PRINCIPAL FINANCIAL GROUP INC | $2,032,088 | 51,945 | 0.32% | Shares |
| OMERS ADMINISTRATION Corp | $2,030,328 | 51,900 | 0.32% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $1,989,800 | 50,864 | 0.31% | Shares |
| Woodline Partners LP | $1,956,000 | 50,000 | 0.31% | Shares |
| Connor, Clark & Lunn Investment Management Ltd. | $1,920,636 | 49,096 | 0.30% | Shares |
| SEGALL BRYANT & HAMILL, LLC | $1,794,747 | 45,878 | 0.28% | Shares |
Activists & 5%+ owners 5 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | Jan. 27, 2005 | · | Initial filing | Passive investment | SEC |
| I.R.S.Identification Nos. of above persons (entities only). FRAZIER HEALTHCARE II, L.P., I.R.S.Identification Nos. of above persons (entities only). FHM II, L.L.C., I.R.S.Identification Nos. of above persons (entities only). FRAZIER HEALTHCARE IV, L.P., I.R.S.Identification Nos. of above persons (entities only). FRAZIER AFFILIATES IV, L.P.., I.R.S.Identification Nos. of above persons (entities only). FHM IV, L.P., I.R.S.Identification Nos. of above persons (entities only). FHM IV, L.L.C., I.R.S.Identification Nos. of above persons (entities only). FRAZIER MANAGEMENT, L.L.C., I.R.S.Identification Nos. of above persons (entities only). FRAZIER & COMPANY, INC., I.R.S.Identification Nos. of above persons (entities only). ALAN D. FRAZIER | April 14, 2004 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | July 7, 2003 | · | Initial filing | Board campaign | SEC |
| MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III Parallel Fund, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG, MPM Asset Management Investors 2003 BVIII, LLC, MPM BioEquities Master Fund, L.P., MPM BioVentures III GP, LP, MPM BioVentures III LLC, MPM BioEquities GP, LP, MPM BioEquities GP, LLC, Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Robert Liptak, Nick Simon, III, Michael Steinmetz, Kurt von Emster, Kurt Wheeler | July 7, 2003 | · | Initial filing | Board campaign | SEC |
| MPM Bio Ventures III, L.P., MPM Bio Ventures III-QP, L.P., MPM Bio Ventures III Parallel Fund, L.P., MPM Bio Ventures III GmbH & Co. Beteiligungs KG, MPM Asset Management Investors 2003 BVIII, LLC, MPM BioEquities Master Fund, L.P., MPM Bio Ventures III GP, L.P., MPM Bio Ventures III LLC, MPM BioEquities GP, L.P., MPM BioEquities GP, LLC, Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Robert Liptak, Nicholas Simon, III, Michael Steinmetz, Kurt von Emster, Kurt Wheeler | May 14, 2003 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 41 insiders · 20 officers · 20 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Raul R Rodriguez | CEO, President | Sept. 1, 2026 F | 273,362 | 0 | 0 | $0 |
| James M Gower | CEO & Board Chairman | Feb. 27, 2014 A | 180,676 | 0 | 0 | $0 |
| Dean L Schorno | EVP & Chief Financial Officer | Sept. 2, 2026 M | 82,962 | 0 | 0 | $0 |
| Ryan D Maynard | EVP & CFO | Nov. 3, 2017 M | 0 | 0 | 0 | $0 |
| James H Welch | CFO, VP & Secretary | Jan. 25, 2006 A | 3,757 | 0 | 0 | $0 |
| David A Santos | EVP, Chief Commercial Officer | Sept. 1, 2026 F | 61,622 | 0 | 0 | $0 |
| Raymond J. Furey | EVP, GC, CCO & Corp Sec | Sept. 1, 2026 F | 50,559 | 0 | 0 | $0 |
| Alison L. Hannah | EVP, Chief Medical Officer | July 8, 2026 A | 35,025 | 0 | 0 | $0 |
| Lisa Rojkjaer | EVP, Chief Medical Officer | June 17, 2026 A | 34,003 | 0 | 0 | $0 |
| Wolfgang Dummer | EVP & CMO | Feb. 2, 2023 S | 72,459 | 0 | 0 | $0 |
| Dolly Vance | EVP Corp. Affairs, G.C., Sect. | Sept. 14, 2022 A | 60,260 | 0 | 0 | $0 |
| Nelson Cabatuan | VP,Finance & Princ.Acctg. Off. | May 14, 2020 A | 58 | 0 | 0 | $0 |
| Eldon C. Mayer III | EVP & Chief Commercial Officer | Nov. 18, 2019 A | 215,000 | 0 | 0 | $0 |
| Joseph Lasaga | Sr.VP Bus.Dev.Alliance Mgmt. | Nov. 18, 2019 A | · | 0 | 0 | $0 |
| Esteban Masuda | Sr. VP Research | Nov. 18, 2019 S | · | 0 | 0 | $0 |
| Stacy Markel | EVP Human Resources | March 20, 2019 A | · | 0 | 0 | $0 |
| Anne-Marie Duliege | EVP & Chief Medical Officer | March 20, 2019 A | 0 | 0 | 0 | $0 |
| Donald G Payan | EVP, Pres. Discovery&Research | Aug. 30, 2016 S | 53,031 | 0 | 0 | $0 |
| Elliot B Grossbard | EVP, CMO | Jan. 26, 2016 A | 2,000 | 0 | 0 | $0 |
| Robin D G Cooper | Sr. V.P. Pharmaceutical Scs. | Jan. 31, 2008 A | 9,000 | 0 | 0 | $0 |
| Kamil Ali-Jackson | Director | June 22, 2026 S | 10,125 | 0 | 2 | $-160,425 |
| Mark W Frohlich | Director | May 15, 2026 A | 7,000 | 0 | 0 | $0 |
| Jane Wasman | Director | May 15, 2026 A | 18,250 | 0 | 0 | $0 |
| Anthony Gregg Lapointe | Director | May 15, 2026 A | 18,250 | 0 | 0 | $0 |
| MILLER MICHAEL PATRICK | Director | May 15, 2026 A | 5,937 | 0 | 0 | $0 |
| Walter H Moos | Director | May 15, 2026 A | 18,472 | 0 | 1 | $-145,440 |
| Brian L. Kotzin | Director | May 25, 2024 A | 100,000 | 0 | 0 | $0 |
| LYONS GARY A | Director | May 26, 2023 A | 75,000 | 0 | 0 | $0 |
| Keith Katkin | Director | May 19, 2021 A | 25,000 | 0 | 0 | $0 |
| Bradford S Goodwin | Director | May 19, 2021 A | 35,000 | 0 | 0 | $0 |
| Peter S Ringrose | Director | May 17, 2018 A | · | 0 | 0 | $0 |
| SHERWIN STEPHEN A | Director | May 11, 2016 A | · | 0 | 0 | $0 |
| Hollings Renton | Director | May 15, 2013 A | · | 0 | 0 | $0 |
| Jean Deleage | Director | May 28, 2010 A | 697 | 0 | 0 | $0 |
| Alan D Frazier | Director | Aug. 7, 2006 A | 10,905 | 0 | 0 | $0 |
| Nicholas J Simon III | Director | June 3, 2005 A | 0 | 0 | 0 | $0 |
| Dennis Henner | Director | Jan. 5, 2005 S | 0 | 0 | 0 | $0 |
| Michael Steinmetz | 10% owner | Aug. 2, 2004 S | 1,833,597 | 0 | 0 | $0 |
| Nicholas Galakatos | 10% owner | July 2, 2004 S | 1,833,597 | 0 | 0 | $0 |
| Luke Evnin | 10% owner | July 2, 2004 S | 1,833,597 | 0 | 0 | $0 |
| ANSBERT GADICKE | 10% owner | July 2, 2004 J | 0 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 31 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1.54% | 41,313 NS | July 31, 2026 | N-PORT |
| IDNA · iShares Trust | 0.82% | 44,383 SH | Sept. 11, 2026 | Daily |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.53% | 2,596 SH | Oct. 2, 2026 | Daily |
| IWC · iShares Trust | 0.21% | 62,481 SH | Sept. 11, 2026 | Daily |
| JPSE · J.P. Morgan Exchange-Traded Fund Tr… | 0.18% | 29,124 NS | July 31, 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.16% | 22,093 NS | July 31, 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0.13% | 23,978 SH | Aug. 19, 2026 | Daily |
| CALF · Pacer Funds Trust | 0.09% | 84,790 NS | July 31, 2026 | N-PORT |
| IBB · iShares Trust | 0.06% | 136,671 SH | Sept. 11, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.06% | 1,309 SH | Oct. 2, 2026 | Daily |
| VFMO · VANGUARD WELLINGTON FUND | 0.05% | 27,549 SH | Aug. 19, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.05% | 15,998 SH | Aug. 19, 2026 | Daily |
| PWS · Pacer Funds Trust | 0.05% | 302 NS | July 31, 2026 | N-PORT |
| IWM · iShares Trust | 0.03% | 473,179 SH | Sept. 11, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.02% | 12,438 SH | Oct. 2, 2026 | Daily |
| RSSL · Global X Funds | 0.02% | 8,801 NS | July 31, 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.02% | 105,855 SH | Aug. 19, 2026 | Daily |
| TECB · iShares Trust | 0.02% | 1,868 SH | Sept. 11, 2026 | Daily |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.01% | 619 SH | Oct. 2, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 212,359 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.01% | 54,159 SH | Aug. 19, 2026 | Daily |
| DFAS · Dimensional ETF Trust | 0.01% | 32,659 NS | July 31, 2026 | N-PORT |
| IWV · iShares Trust | 0.00% | 6,553 SH | Sept. 9, 2026 | Daily |
| DFAC · Dimensional ETF Trust | 0.00% | 16,178 NS | July 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.00% | 22,835 SH | Sept. 11, 2026 | Daily |
| DFAU · Dimensional ETF Trust | 0.00% | 3,010 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 699 NS | July 31, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 555,846 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 1,629 SH | Aug. 19, 2026 | Daily |
| DFUV · Dimensional ETF Trust | 0.00% | 112 NS | July 31, 2026 | N-PORT |
| IWN · iShares Trust | · | 171,420 SH | Sept. 11, 2026 | Daily |
RIGL Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 11 analysts
BUY
Median target
$55.00
+16.6%
4 36.4%
Strong Buy
4 36.4%
Buy
3 27.3%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
5 analysts · 2026-09-28Mean target $63.00 +33.6%
Now
Current price $47.15
Low$43.00
Mean$63.00
High$85.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| RIGL | $784M | 2.2 | 64.1% | 124.7% | 155.1% | · |
| KURA | $913M | -3.3 | 25.2% | -413.0% | -116.2% | · |
| CRVS | $575M | -14.5 | · | · | -21.6% | · |
| GLUE | $1.03B | · | 63.5% | -31.2% | -15.4% | · |
| JBIO | $761M | -4.8 | · | · | -47.7% | · |
| SANA | $1.09B | -4.2 | · | · | -172.3% | · |
| OBX | · | · | · | · | · | · |
| ARDX | $1.42B | -22.4 | 22.1% | -15.1% | -40.2% | · |
| AVTX | $336M | -3.1 | -86.6% | -132642.4% | -83.4% | · |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 4, 2026